Loading
A phase 3 trial of SYS6010 and osimertinib in lung cancer, run by CSPC Megalith Biopharmaceutical Co.,Ltd., not yet recruiting.
A Phase III Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC is a phase 3, randomised interventional study registered as NCT07376382 by CSPC Megalith Biopharmaceutical Co.,Ltd., with a registry enrolment figure of 680 participants, started 2026-06-01 and due to reach its primary completion in 2026-12-12. Interventions recorded: SYS6010; Osimertinib; platinum-pemetrexed. Conditions listed: NSCLC. Primary outcome: Progression Free Survival(PFS) evaluated by IRC. Lung eligibility wording from the registry: "Patients with pathologically confirmed locally advanced or metastatic NSCLC, including: patients with stage IIIB or IIIC based on AJCC staging version 8 who are not suitable for surgical resection or radical chemoradiotherapy, or patients with stage IV NSCLC". No results are recorded here; the registry entry is the source.
Shares SYS6010, CSPC Pharmaceutical Group, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares SYS6010, CSPC Pharmaceutical Group, Osimertinib, EGFR-mutated non-small-cell lung cancer and the tag lung-deep-dive.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.